AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI

Detalhes bibliográficos
Autor(a) principal: MILENA PEREIRA BATISTA
Data de Publicação: 2023
Tipo de documento: Trabalho de conclusão de curso
Idioma: por
Título da fonte: Repositório Institucional da UFMS
Texto Completo: https://repositorio.ufms.br/handle/123456789/7686
Resumo: The protozoan Trypanosoma cruzi is the etiological agent of Chagas Disease, one of the diseases considered by the World Health Organization to be neglected. The parasite has the ability to cause parasitemia and eventually invade tissues. The drugs used to treat this disease are effective, but cause many adverse effects, which is why adherence to treatment is low. Faced with this scenario, there is a search for pharmacotherapeutic alternatives, but this path comes up against common barriers to the discovery of new drugs, such as time and resources. For this reason, drug repositioning is a viable alternative, as it requires less time and/or resources. Levamisole is a drug from the anthelmintic class, with an immunomodulatory effect, used to treat ascariasis. Recent articles also point to its activity in forms of Giardia sp. Its mechanism of action is throughenzymatic interference in the parasite and, because of this, the possibility of it having activity against strains of Trypanosoma cruzi is being investigated. The drug’s activity was assessed in three ways: through the MTS test, with a concentration of 200ug/mL of the drug and incubation at 37°C for 72 hours; counting parasites in a Neubauer chamber with a concentration of 400ug/mL of the drug; and analyzing the morphologyof the protozoa using a microscope slide fixed with 4% paraformaldehyde and stainedusing the Panocyte method. A culture without the addition of the drug was used as a control for the three methods. Parasite growth was checked at 24 hours and 72 hours and, at the end, a morphological analysis was carried out. Based on the results of the tests, the interaction between the drug and the parasite was evaluated. Based on this evaluation, it will be possible in the future to determine the effect of this drug as an immunomodulator in cells infected with the parasite.
id UFMS_81e7ba01fda215504c9ca377582b9c38
oai_identifier_str oai:repositorio.ufms.br:123456789/7686
network_acronym_str UFMS
network_name_str Repositório Institucional da UFMS
repository_id_str 2124
spelling 2023-12-03T21:13:20Z2023-12-03T21:13:20Z2023https://repositorio.ufms.br/handle/123456789/7686The protozoan Trypanosoma cruzi is the etiological agent of Chagas Disease, one of the diseases considered by the World Health Organization to be neglected. The parasite has the ability to cause parasitemia and eventually invade tissues. The drugs used to treat this disease are effective, but cause many adverse effects, which is why adherence to treatment is low. Faced with this scenario, there is a search for pharmacotherapeutic alternatives, but this path comes up against common barriers to the discovery of new drugs, such as time and resources. For this reason, drug repositioning is a viable alternative, as it requires less time and/or resources. Levamisole is a drug from the anthelmintic class, with an immunomodulatory effect, used to treat ascariasis. Recent articles also point to its activity in forms of Giardia sp. Its mechanism of action is throughenzymatic interference in the parasite and, because of this, the possibility of it having activity against strains of Trypanosoma cruzi is being investigated. The drug’s activity was assessed in three ways: through the MTS test, with a concentration of 200ug/mL of the drug and incubation at 37°C for 72 hours; counting parasites in a Neubauer chamber with a concentration of 400ug/mL of the drug; and analyzing the morphologyof the protozoa using a microscope slide fixed with 4% paraformaldehyde and stainedusing the Panocyte method. A culture without the addition of the drug was used as a control for the three methods. Parasite growth was checked at 24 hours and 72 hours and, at the end, a morphological analysis was carried out. Based on the results of the tests, the interaction between the drug and the parasite was evaluated. Based on this evaluation, it will be possible in the future to determine the effect of this drug as an immunomodulator in cells infected with the parasite.O protozoário Trypanosoma cruzi é o agente etiológico da Doença de Chagas, uma das doenças consideradas pela Organização Mundial da Saúde como negligenciadas. O parasito tem a capacidade de causar parasitemia e, eventualmente, invadir tecidos. Os medicamentos destinados ao tratamento para essa doença são eficazes, mas causam muitos efeitos adversos, por isso a adesão ao tratamento é baixa. Diante desse cenário, há a busca por alternativas farmacoterapêuticas, porém esse caminho esbarra em barreiras comuns à descoberta de novos medicamentos, como tempo e recursos. Por isso, o reposicionamento de fármacos se mostra uma alternativa viável, pois demanda menos tempo e/ou recursos. O levamisol é um medicamento da classe dos anti-helmínticos, com efeito imunomodulador, usado para o tratamento de ascaridíase. Artigos recentes ainda apontam sua atividade em formas de Giardia sp. Seu mecanismo de ação se dá por interferência enzimática no parasito e, por causa disso, investiga-se a possibilidade de ter atividade contra cepas de Trypanosoma cruzi. A atividade do fármaco foi avaliada de três formas: através de teste com MTS, com a concentração de 200ug/mL do fármaco e incubação a 37°C por 72 horas; contagem de parasitos emcâmara de Neubauer com concentração de 400ug/mL do fármaco; e análise da morfologia do protozoário através de lâmina de microscopia fixada com paraformaldeído a 4% e corada pelo método Panócito. Como controle, para os três métodos, foi utilizada cultura sem adição do fármaco. O crescimento do parasito foi verificado em 24 horas e em 72 horas e, ao final, foi feita a análise morfológica. A partir dos resultados dos testes foi avaliada a interação desse fármaco com o parasito. Com base nessa avaliação, será possível, futuramente, estipular o efeito desse fármaco como imunomodulador em células infectadas com o parasito.Fundação Universidade Federal de Mato Grosso do SulUFMSCiências BiológicasTrypanosoma cruziLevamisolDoença de Chagas.AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZIinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesisALDA MARIA TEIXEIRA FERREIRAMILENA PEREIRA BATISTAinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMSinstname:Universidade Federal de Mato Grosso do Sul (UFMS)instacron:UFMSORIGINAL9032.pdf9032.pdfapplication/pdf918845https://repositorio.ufms.br/bitstream/123456789/7686/-1/9032.pdf6e6fb2bc7ca121bde0801849dccc1a51MD5-1123456789/76862023-12-03 17:13:20.905oai:repositorio.ufms.br:123456789/7686Repositório InstitucionalPUBhttps://repositorio.ufms.br/oai/requestri.prograd@ufms.bropendoar:21242023-12-03T21:13:20Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)false
dc.title.pt_BR.fl_str_mv AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
title AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
spellingShingle AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
MILENA PEREIRA BATISTA
Trypanosoma cruzi
Levamisol
Doença de Chagas.
Ciências Biológicas
title_short AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
title_full AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
title_fullStr AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
title_full_unstemmed AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
title_sort AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
author MILENA PEREIRA BATISTA
author_facet MILENA PEREIRA BATISTA
author_role author
dc.contributor.advisor1.fl_str_mv ALDA MARIA TEIXEIRA FERREIRA
dc.contributor.author.fl_str_mv MILENA PEREIRA BATISTA
contributor_str_mv ALDA MARIA TEIXEIRA FERREIRA
dc.subject.por.fl_str_mv Trypanosoma cruzi
Levamisol
Doença de Chagas.
topic Trypanosoma cruzi
Levamisol
Doença de Chagas.
Ciências Biológicas
dc.subject.classification.pt_BR.fl_str_mv Ciências Biológicas
description The protozoan Trypanosoma cruzi is the etiological agent of Chagas Disease, one of the diseases considered by the World Health Organization to be neglected. The parasite has the ability to cause parasitemia and eventually invade tissues. The drugs used to treat this disease are effective, but cause many adverse effects, which is why adherence to treatment is low. Faced with this scenario, there is a search for pharmacotherapeutic alternatives, but this path comes up against common barriers to the discovery of new drugs, such as time and resources. For this reason, drug repositioning is a viable alternative, as it requires less time and/or resources. Levamisole is a drug from the anthelmintic class, with an immunomodulatory effect, used to treat ascariasis. Recent articles also point to its activity in forms of Giardia sp. Its mechanism of action is throughenzymatic interference in the parasite and, because of this, the possibility of it having activity against strains of Trypanosoma cruzi is being investigated. The drug’s activity was assessed in three ways: through the MTS test, with a concentration of 200ug/mL of the drug and incubation at 37°C for 72 hours; counting parasites in a Neubauer chamber with a concentration of 400ug/mL of the drug; and analyzing the morphologyof the protozoa using a microscope slide fixed with 4% paraformaldehyde and stainedusing the Panocyte method. A culture without the addition of the drug was used as a control for the three methods. Parasite growth was checked at 24 hours and 72 hours and, at the end, a morphological analysis was carried out. Based on the results of the tests, the interaction between the drug and the parasite was evaluated. Based on this evaluation, it will be possible in the future to determine the effect of this drug as an immunomodulator in cells infected with the parasite.
publishDate 2023
dc.date.accessioned.fl_str_mv 2023-12-03T21:13:20Z
dc.date.available.fl_str_mv 2023-12-03T21:13:20Z
dc.date.issued.fl_str_mv 2023
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/bachelorThesis
format bachelorThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.ufms.br/handle/123456789/7686
url https://repositorio.ufms.br/handle/123456789/7686
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Fundação Universidade Federal de Mato Grosso do Sul
dc.publisher.initials.fl_str_mv UFMS
dc.publisher.country.pt_BR.fl_str_mv
publisher.none.fl_str_mv Fundação Universidade Federal de Mato Grosso do Sul
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMS
instname:Universidade Federal de Mato Grosso do Sul (UFMS)
instacron:UFMS
instname_str Universidade Federal de Mato Grosso do Sul (UFMS)
instacron_str UFMS
institution UFMS
reponame_str Repositório Institucional da UFMS
collection Repositório Institucional da UFMS
bitstream.url.fl_str_mv https://repositorio.ufms.br/bitstream/123456789/7686/-1/9032.pdf
bitstream.checksum.fl_str_mv 6e6fb2bc7ca121bde0801849dccc1a51
bitstream.checksumAlgorithm.fl_str_mv MD5
repository.name.fl_str_mv Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)
repository.mail.fl_str_mv ri.prograd@ufms.br
_version_ 1815448015623684096